Aminex Therapeutics
Aminex Therapeutics, Inc.
Aminex Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies. Their primary strategy is to overcome immune system suppression within the tumor microenvironment by targeting and depleting polyamines, thereby enabling the body's own immune system to attack cancer cells.
Products & Team
AMXT 1501 + DFMO Combination Therapy
The flagship product is an oral, small molecule therapy that combines AMXT 1501, a proprietary polyamine uptake inhibitor, with DFMO (eflornithine), a polyamine synthesis inhibitor. This dual-agent approach works synergistically to significantly lower polyamine levels in cancer cells and the surrounding tumor microenvironment, which in turn suppresses myeloid-derived suppressor cells (MDSCs) and restores the innate immune system's ability to fight solid tumors.
It addresses a critical failure point in cancer treatment where the tumor creates an environment that suppresses the immune system. By reversing this suppression, the therapy reactivates the body's natural defense mechanisms to attack the cancer.
Patients with solid tumors often face treatments that are ineffective because the cancer has suppressed the local immune system, preventing immune cells from attacking the tumor. This leads to tumor progression and limited therapeutic options.